Brought to you by 
IPO nets $295mm for Gossamer Bio
07 May 2019
Executive Summary
Gossamer Bio Inc. (developing therapies for immune diseases, inflammation, and cancer) netted $295mm through its initial public offering of 19.8mm common shares (including the overallotment) at $16. The company had originally intended to sell 14mm shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com